

United States  
Securities and Exchange Commission  
Washington, DC 20549

Form 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): October 20, 2023

PERFICIENT, INC.  
(Exact Name of Registrant as Specified in its Charter)

Delaware

001-15169

74-2853258

(State or Other Jurisdiction of Incorporation)

(Commission File Number)

(IRS Employer Identification No.)

555 Maryville University Drive  
Suite 600  
Saint Louis, Missouri 63141  
(Address of principal executive offices)  
(314) 529-3600  
(Registrant's telephone number, including area code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, \$0.001 par value	PRFT	The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

## ITEM 7.01 REGULATION FD DISCLOSURE

On October 20, 2023, Perficient, Inc. (the “Company”) issued a press release announcing that the Company entered into a Stock Purchase Agreement (the “Agreement”), by and among the Company, SMEDIX, Inc., a California corporation (“SMEDIX”), and the sole shareholder of SMEDIX (the “Shareholder”). Pursuant to the Agreement, the Company will acquire all of the outstanding capital stock of SMEDIX.

The parties are targeting a closing in January 2024, subject to customary closing conditions and regulatory approval. The Agreement includes customary representations, warranties and covenants by the parties and customary termination rights for the Company and the Shareholder.

A copy of the press release issued by the Company announcing the signing of the Agreement is furnished herewith as Exhibit 99.1 and incorporated herein by reference.

In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall such information and Exhibit be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

## ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS

(d) Exhibits.

<b>Exhibit Number</b>	<b>Description</b>
<a href="#">99.1</a>	Perficient, Inc. Press Release, dated October 20, 2023

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PERFICIENT, INC.

Date: October 20, 2023

By: /s/ Paul E. Martin  
Paul E. Martin  
Chief Financial Officer

For more information, please contact:  
Bill Davis, Vice President  
314-529-3555

**Perficient Reaches Definitive Agreement to Acquire SMEDIX, INC.**  
*Strengthens Healthcare Industry Software Development Capabilities and  
Adds Global Delivery Capacity in Eastern Europe*

**SAINT LOUIS (Oct. 20, 2023)** – Perficient, Inc. (Nasdaq: PRFT) (“Perficient”), the leading digital consultancy transforming the world’s largest enterprises and biggest brands, announced today it has entered into a purchase agreement to acquire SMEDIX, Inc. (“SMEDIX”), an approximately \$12 million revenue healthcare software engineering firm headquartered in San Diego, California, with offshore operations located in Cluj-Napoca, Romania.

“We’re thrilled to continue to strengthen our healthcare industry digital capabilities, enhance our global delivery capacity, and expand further within Eastern Europe with the strategic acquisition of SMEDIX,” said CEO Tom Hogan. “Nearly 175 skilled global professionals are joining Perficient and bringing their award-winning agile software development, testing and support experience capabilities to the team.”

The acquisition of SMEDIX will:

- Strengthen Perficient’s healthcare industry software development capabilities and capacity with enhanced agile software design, development, testing and support for biomedical and healthcare customers, enhancing patient care, reducing costs and accelerating innovation;
- Broaden Perficient’s clinical diagnostic and medical device product offerings, bringing specializations in medical software development, systems engineering, data analytics and machine learning, bioinformatics, cloud and IoT applications, product compliance, and mobile applications;
- Expand Perficient’s presence in Eastern Europe, adding an offshore software development location in Cluj-Napoca, Romania;
- Add nearly 175 skilled global professionals; and
- Bring strategic client relationships 100% focused in the biomedical and healthcare industry.

SMEDIX President and CEO Fayez Sweiss will join Perficient in a key leadership role.

“Perficient is well known for its world class end-to-end digital consulting capabilities, deep healthcare and life sciences industry expertise, and unmatched global delivery,” said Sweiss. “We’re excited to join forces to not only deepen our healthcare digital experience and expertise, but also to further help our clients enhance patient care through innovative software solutions and technologies.”

The parties are targeting a closing in January 2024, subject to customary closing conditions and regulatory approval. The Agreement includes customary representations, warranties and covenants by the parties and customary termination rights for the Company and the selling shareholder.

#### **About Perficient**

Perficient is the leading global digital consultancy. We imagine, create, engineer, and run digital transformation solutions that help our clients exceed customers’ expectations, outpace competition, and grow their business. With unparalleled strategy, creative, and technology capabilities, we bring big thinking and innovative ideas, along with a practical approach to help the world’s largest enterprises and biggest brands succeed. Traded on the Nasdaq Global Select Market, Perficient is a member of the Russell 2000 index and the S&P SmallCap 600 index. For more information, visit [www.perficient.com](http://www.perficient.com).

#### **Safe Harbor Statement**

Some of the statements contained in this news release that are not purely historical statements discuss future expectations or state other forward-looking information related to financial results and business outlook for 2023. Those statements are subject to known and unknown risks, uncertainties, and other factors that could cause the actual results to differ materially from those contemplated by the statements. The forward-looking information is based on management’s current intent, belief, expectations, estimates, and projections regarding our company and our industry. You should be aware that those statements only reflect our predictions. Actual events or results may

differ substantially. Important factors that could cause our actual results to be materially different from the forward-looking statements include (but are not limited to) those disclosed under the heading "Risk Factors" in our most recently filed annual report on Form 10-K and other securities filings.